$NKTR
NEKTAR THERAPEUTICS

2021 Q2 Form 10-Q Financial Statement

#000090670921000014 Filed on August 06, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $28.33M $48.85M
YoY Change -42.0% 109.51%
Cost Of Revenue $7.667M $5.773M
YoY Change 32.81% 15.05%
Gross Profit $20.66M $43.07M
YoY Change -52.03% 135.42%
Gross Profit Margin 72.94% 88.18%
Selling, General & Admin $29.56M $24.30M
YoY Change 21.63% 7.52%
% of Gross Profit 143.03% 56.41%
Research & Development $101.3M $96.44M
YoY Change 5.06% -9.61%
% of Gross Profit 490.31% 223.88%
Depreciation & Amortization $3.590M $3.200M
YoY Change 12.19% 6.67%
% of Gross Profit 17.37% 7.43%
Operating Expenses $101.3M $96.44M
YoY Change 5.06% -9.61%
Operating Profit -$110.2M -$77.71M
YoY Change 41.82% -29.97%
Interest Expense $0.00 $647.0K
YoY Change -100.0% -87.63%
% of Operating Profit
Other Income/Expense, Net -$14.96M -$2.147M
YoY Change 596.65% -374.2%
Pretax Income -$125.2M -$79.86M
YoY Change 56.73% -27.53%
Income Tax $357.0K $144.0K
% Of Pretax Income
Net Earnings -$125.5M -$80.00M
YoY Change 56.9% -27.46%
Net Earnings / Revenue -443.06% -163.78%
Basic Earnings Per Share -$0.69 -$0.45
Diluted Earnings Per Share -$0.69 -$0.45
COMMON SHARES
Basic Shares Outstanding 182.7M shares 178.3M shares
Diluted Shares Outstanding 182.7M shares 178.3M shares

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.000B $1.038B
YoY Change -3.69% -31.48%
Cash & Equivalents $152.3M $58.21M
Short-Term Investments $847.7M $980.2M
Other Short-Term Assets $12.60M $37.77M
YoY Change -66.65% 185.85%
Inventory $14.62M $12.58M
Prepaid Expenses
Receivables $28.87M $47.25M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.056B $1.152B
YoY Change -8.32% -27.86%
LONG-TERM ASSETS
Property, Plant & Equipment $58.60M $61.37M
YoY Change -4.52% -6.24%
Goodwill $76.50M $76.50M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $57.40M $172.2M
YoY Change -66.67% -37.68%
Other Assets $344.0K $1.413M
YoY Change -75.65% -41.13%
Total Long-Term Assets $315.2M $442.9M
YoY Change -28.83% -11.92%
TOTAL ASSETS
Total Short-Term Assets $1.056B $1.152B
Total Long-Term Assets $315.2M $442.9M
Total Assets $1.371B $1.595B
YoY Change -14.02% -24.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $19.70M $19.25M
YoY Change 2.36% 105.93%
Accrued Expenses $111.3M $103.0M
YoY Change 8.08% 9.46%
Deferred Revenue $1.757M
YoY Change -82.25%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $131.0M $124.0M
YoY Change 5.7% 9.34%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $4.016M $2.239M
YoY Change 79.37% 248.21%
Total Long-Term Liabilities $4.016M $2.239M
YoY Change 79.37% 248.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $131.0M $124.0M
Total Long-Term Liabilities $4.016M $2.239M
Total Liabilities $466.4M $338.6M
YoY Change 37.72% -37.58%
SHAREHOLDERS EQUITY
Retained Earnings -$2.558B -$2.083B
YoY Change 22.76% 26.08%
Common Stock $3.466B $3.339B
YoY Change 3.81% 4.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $905.0M $1.256B
YoY Change
Total Liabilities & Shareholders Equity $1.371B $1.595B
YoY Change -14.02% -24.04%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$125.5M -$80.00M
YoY Change 56.9% -27.46%
Depreciation, Depletion And Amortization $3.590M $3.200M
YoY Change 12.19% 6.67%
Cash From Operating Activities -$82.89M -$83.90M
YoY Change -1.21% 55.66%
INVESTING ACTIVITIES
Capital Expenditures -$3.257M -$2.700M
YoY Change 20.63% -76.92%
Acquisitions
YoY Change
Other Investing Activities $76.27M $159.7M
YoY Change -52.24% 332.79%
Cash From Investing Activities $72.91M $157.0M
YoY Change -53.56% 520.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.12M -242.0M
YoY Change -105.01% -3415.07%
NET CHANGE
Cash From Operating Activities -82.89M -83.90M
Cash From Investing Activities 72.91M 157.0M
Cash From Financing Activities 12.12M -242.0M
Net Change In Cash 2.147M -168.9M
YoY Change -101.27% 692.96%
FREE CASH FLOW
Cash From Operating Activities -$82.89M -$83.90M
Capital Expenditures -$3.257M -$2.700M
Free Cash Flow -$79.63M -$81.20M
YoY Change -1.93% 92.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0000906709
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-24006
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
183801441 shares
dei Entity Registrant Name
EntityRegistrantName
NEKTAR THERAPEUTICS
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3134940
dei Entity Address Address Line1
EntityAddressAddressLine1
455 Mission Bay Boulevard South
dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94158
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
482-5300
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
NKTR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
152345000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
198955000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
847720000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
862941000 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
28871000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
38889000 USD
CY2021Q2 us-gaap Inventory Net
InventoryNet
14616000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
15292000 USD
CY2021Q2 us-gaap Other Assets Current
OtherAssetsCurrent
12596000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
21928000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
1056148000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
1138005000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
57397000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
136662000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
58599000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
59662000 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
122362000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
126476000 USD
CY2021Q2 us-gaap Goodwill
Goodwill
76501000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
76501000 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
344000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1461000 USD
CY2021Q2 us-gaap Assets
Assets
1371351000 USD
CY2020Q4 us-gaap Assets
Assets
1538767000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
19701000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
22139000 USD
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
28665000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14532000 USD
CY2021Q2 nktr Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
41085000 USD
CY2020Q4 nktr Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
44207000 USD
CY2021Q2 nktr Accrued Contract Manufacturing Expense Current
AccruedContractManufacturingExpenseCurrent
8392000 USD
CY2020Q4 nktr Accrued Contract Manufacturing Expense Current
AccruedContractManufacturingExpenseCurrent
11310000 USD
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
16404000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9676000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16776000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
13915000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
131023000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
115779000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
131658000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
136373000 USD
CY2021Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
11607000 USD
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 USD
CY2021Q2 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
188072000 USD
CY2020Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
200340000 USD
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4016000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8980000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
466376000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
461472000 USD
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q2 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0 shares
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
183773000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
180091000 shares
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
18000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
18000 USD
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3466001000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3388730000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3400000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2295000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2557644000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2309158000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
904975000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1077295000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1371351000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1538767000 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28330000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
48847000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51977000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
99420000 USD
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7667000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5773000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13423000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9584000 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
101313000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96436000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
196917000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
205423000 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29555000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24347000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
61234000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50564000 USD
CY2021Q2 nktr Impairment Of Equipment And Other Costs For Terminated Program
ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram
0 USD
CY2020Q2 nktr Impairment Of Equipment And Other Costs For Terminated Program
ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram
0 USD
nktr Impairment Of Equipment And Other Costs For Terminated Program
ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram
0 USD
nktr Impairment Of Equipment And Other Costs For Terminated Program
ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram
45189000 USD
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
138535000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
126556000 USD
us-gaap Costs And Expenses
CostsAndExpenses
271574000 USD
us-gaap Costs And Expenses
CostsAndExpenses
310760000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-110205000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-77709000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-219597000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-211340000 USD
CY2021Q2 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
13089000 USD
CY2020Q2 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
6691000 USD
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
26385000 USD
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
13659000 USD
CY2021Q2 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-2713000 USD
CY2020Q2 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0 USD
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-4312000 USD
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0 USD
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
845000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5191000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2257000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13543000 USD
CY2021Q2 us-gaap Interest Expense
InterestExpense
0 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
647000 USD
us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
6851000 USD
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-14957000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2147000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-28440000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6967000 USD
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-125162000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-79856000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-248037000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-218307000 USD
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
357000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
144000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
449000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
344000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-125519000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-80000000 USD
us-gaap Net Income Loss
NetIncomeLoss
-248486000 USD
us-gaap Net Income Loss
NetIncomeLoss
-218651000 USD
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
182698000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
182698000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
178327000 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
178327000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
182038000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
182038000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
177755000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
177755000 shares
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-125519000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-80000000 USD
us-gaap Net Income Loss
NetIncomeLoss
-248486000 USD
us-gaap Net Income Loss
NetIncomeLoss
-218651000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-64000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
7688000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-830000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2567000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-215000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-96000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-275000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-847000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-279000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7592000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1105000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1720000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-125798000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72408000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-249591000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-216931000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1405391000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
11347000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24211000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-144523000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
1296426000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7826000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24396000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72408000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
1256240000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1077295000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
17106000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23898000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-123793000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
994506000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
12553000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23714000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-125798000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
904975000 USD
us-gaap Profit Loss
ProfitLoss
-248486000 USD
us-gaap Profit Loss
ProfitLoss
-218651000 USD
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
39254000 USD
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
17579000 USD
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
26385000 USD
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
13659000 USD
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-4312000 USD
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
5795000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
47612000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
48607000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
7090000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
7692000 USD
nktr Impairment Of Equipment From Terminated Program
ImpairmentOfEquipmentFromTerminatedProgram
0 USD
nktr Impairment Of Equipment From Terminated Program
ImpairmentOfEquipmentFromTerminatedProgram
20351000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-4090000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
782000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10018000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10443000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-676000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-81000 USD
nktr Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
-2260000 USD
nktr Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
-4245000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-11585000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
27214000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2101000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
425000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
14133000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
12469000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-3496000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
8952000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-605000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3790000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-159986000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-161978000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
527887000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
543631000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
612419000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
860330000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
5035000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
41700000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6157000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3594000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
83410000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
354805000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
28523000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
19120000 USD
us-gaap Proceeds From Derivative Instrument Financing Activities
ProceedsFromDerivativeInstrumentFinancingActivities
1500000 USD
us-gaap Proceeds From Derivative Instrument Financing Activities
ProceedsFromDerivativeInstrumentFinancingActivities
0 USD
us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
0 USD
us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
250000000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30023000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-230880000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-57000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-104000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-46610000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38157000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
198955000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
96363000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
152345000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58206000 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Interest Paid Net
InterestPaidNet
9742000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1057000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2133000 USD
CY2021Q2 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
1100000000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.</span></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders’ equity.</span></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Concentrations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. As of June 30, 2021, our accounts receivable includes $25.0 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS) and $3.4 million under customer contracts from our collaboration partners. As of December 31, 2020, our accounts receivable included $38.7 million for unbilled net expense reimbursements from BMS and $0.2 million from customer contracts. We generally do not require collateral from our customers. We perform a regular review of our customers’ credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three and six months ended June 30, 2021 and 2020. We have not recorded a reserve for credit losses at June 30, 2021 or December 31, 2020.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, a deterioration in this industry could have a material effect on our results of operations and financial position. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer’s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if factors, including the effects of the COVID-19 pandemic, result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div>
CY2021Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
57397000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
136662000 USD
CY2021Q2 nktr Sale Of Stock Value Authorized In Transaction
SaleOfStockValueAuthorizedInTransaction
300000000.0 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
152345000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
198955000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
847720000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
862941000 USD
CY2021Q2 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
1057462000 USD
CY2020Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
1198558000 USD
nktr Debt Investment Maximum Maturity Period
DebtInvestmentMaximumMaturityPeriod
P2Y
nktr Debt Investment Maturity Term
DebtInvestmentMaturityTerm
P1Y
CY2021Q2 us-gaap Cash
Cash
14056000 USD
CY2020Q4 us-gaap Cash
Cash
6285000 USD
CY2021Q2 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
1057462000 USD
CY2020Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
1198558000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1100000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
200000 USD
CY2021Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1996000 USD
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2422000 USD
CY2021Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
9753000 USD
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
10703000 USD
CY2021Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2867000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2167000 USD
CY2021Q2 us-gaap Inventory Net
InventoryNet
14616000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
15292000 USD
CY2021Q2 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
28000 USD
CY2020Q2 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
26275000 USD
nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
82000 USD
nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
53790000 USD
CY2021Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
20500000 USD
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
39300000 USD
CY2020Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
42100000 USD
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
86700000 USD
CY2021Q2 nktr Potential Development And Regulatory Milestones
PotentialDevelopmentAndRegulatoryMilestones
1700000000 USD
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23714000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23371000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
47612000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
48607000 USD
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
157000 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
278000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
49000 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.78
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.88
CY2021Q2 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
1483000 shares
CY2020Q2 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
947000 shares
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
3682000 shares
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
2305000 shares
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18352000 shares
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17115000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18870000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17966000 shares

Files In Submission

Name View Source Status
0000906709-21-000014-index-headers.html Edgar Link pending
0000906709-21-000014-index.html Edgar Link pending
0000906709-21-000014.txt Edgar Link pending
0000906709-21-000014-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nktr-20210630.htm Edgar Link pending
nktr-20210630.xsd Edgar Link pending
nktr-20210630_cal.xml Edgar Link unprocessable
nktr-20210630_def.xml Edgar Link unprocessable
nktr-20210630_htm.xml Edgar Link completed
nktr-20210630_lab.xml Edgar Link unprocessable
nktr-20210630_pre.xml Edgar Link unprocessable
nktr2021-06x30xexx101.htm Edgar Link pending
nktr2021-06x30xexx311.htm Edgar Link pending
nktr2021-06x30xexx312.htm Edgar Link pending
nktr2021-06x30xexx321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending